ViewRay reports preliminary Q4 revenue $35M, consensus $32.67M

Total revenue for the fourth quarter was approximately $35M, primarily from five revenue units, compared to approximately $20M, primarily from three revenue units in the fourth quarter of 2021.Cash and cash equivalents was approximately $142 million as of December 31, 2022. Cash usage in the fourth quarter of 2022 was approximately $18M excluding the term loan net proceeds from the November debt restructuring. Total backlog increased to approximately $380M as of December 31, 2022, compared to approximately $313M as of December 31, 2021."Our team again delivered strong results in Q4. Our innovation, clinical data, and market awareness efforts are driving therapy adoption. We are well positioned to continue our commercial success in 2023," said Scott Drake, president and CEO. "In 2022 the team successfully navigated a challenging environment and delivered on the promise of our mission: ‘To treat and prove what others can’t.’ We look forward to building on our success in the new year."